Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

FirstWord Pharma
firstwordpharma.com > story > 7985869

Spotlight On: Ivonescimab beats expectations to revive practice-changing hopes in NSCLC

14+ hour, 43+ min ago   (13+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7984467

WCLC26: Ivonescimab delivers 27% lower risk of death in Chinese NSCLC study

17+ hour, 38+ min ago   (14+ words) FirstWord Pharma...

FirstWord PHARMA
firstwordpharma.com > story > 7972962

AbbVie aims to expand Qulipta's label into new migraine market

3+ day, 13+ hour ago   (12+ words) FirstWord PHARMA...

FirstWord PHARMA
firstwordpharma.com > story > 7972418

Animal data trigger enrollment pause in Biohaven's epilepsy study

3+ day, 17+ hour ago   (11+ words) FirstWord PHARMA...

FirstWord Pharma
firstwordpharma.com > story > 7967761

Solstice raises $225M to advance next-gen CTLA-4 immunotherapy

4+ day, 19+ hour ago   (10+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7966036

Kura spins out Caspian to take menin inhibitor into diabetes

5+ day, 1+ hour ago   (12+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7965836

Shionogi's regeneration-inducing drug comes up short in acute ischemic stroke study

5+ day, 3+ hour ago   (13+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7963969

Inhibrx touts HNSCC subgroup data, eyes accelerated pathway for OX40 agonist

5+ day, 13+ hour ago   (13+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7965266

Physician Views Preview: How are prescribing patterns changing in COPD?

5+ day, 7+ hour ago   (12+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7960808

AstraZeneca's tozorakimab cuts COPD exacerbations by up to 34% in Phase III

5+ day, 22+ hour ago   (14+ words) FirstWord Pharma...